Wells Fargo is adapting its strategy in light of weakening consumer demand, while still maintaining an optimistic outlook on earnings and growth. The bank raised price targets for companies like Target and CVS Health and maintained a positive stance on several stocks, reflecting confidence despite a mixed Q1 2026 earnings report that showed $21.45 billion in revenue. Furthermore, the removal of the Federal Reserve asset cap positions Wells Fargo for over $1 trillion in loans, enhancing its balance sheet and supporting ambitious revenue goals for the coming years.
“AutoZone · earnings selloff · a buying opportunity · according to Wells Fargo”
“Wells Fargo · warned about · weakening consumer demand”
“New coverage · has leaned supportive · Wells Fargo, Berenberg, Benchmark and others · starting or reiterating positive views”
“Wells Fargo analysts · believe · Time seemed right for a new set of eyes and ideas”
“Wells Fargo · raised its price recommendation on Target Corporation to · $140”
“Wells Fargo · had · retail bank branches · 4093”
“SNAP · Maintained by · Wells Fargo · Price Target Raised to $7.00”
“Wells Fargo · raised · price target on CVS Health Corporation · from $102 to $103”
“Wells Fargo · maintained · rating on shares of CVS Health Corporation · Overweight”
“American Airlines Group Inc. · is rated · Equal Weight · by Wells Fargo”
“American Airlines Group Inc. · has a price target · $17 · set by Wells Fargo”
“Centessa Pharmaceuticals · downgraded by · Wells Fargo · Price Target Raised to $42.00”
